+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anti-Obesity Drugs Market by Product Type, Dosage Form, Route of Administration, End User - Global Forecast 2026-2032- Product Image
Anti-Obesity Drugs Market by Product Type, Dosage Form, Route of Administration, End User - Global Forecast 2026-2032- Product Image
Sale

Anti-Obesity Drugs Market by Product Type, Dosage Form, Route of Administration, End User - Global Forecast 2026-2032

  • Report

  • 198 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 5317899
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Anti-Obesity Drugs Market is projected to reach USD 11.21 Billion in 2026. It is expected to continue growing at a CAGR of 12.32%, reaching USD 22.59 Billion by 2032.

Anti-obesity drugs are moving from a niche weight-management category to a core pillar of chronic cardiometabolic care. The shift is grounded in public-health need: the World Health Organization reported that more than 1 billion people were living with obesity in 2022, and adult obesity has more than doubled since 1990.

Clinical evidence has also changed the market narrative. GLP-1 receptor agonists and dual incretin therapies have demonstrated weight-loss outcomes that exceed older pharmacologic options, while semaglutide 2.4 mg has shown cardiovascular risk-reduction benefits in adults with established cardiovascular disease and overweight or obesity. As obesity is increasingly treated as a chronic, relapsing disease, anti-obesity medications are gaining strategic relevance for pharmaceutical companies, payers, health systems, and digital care providers.

Transformative Shifts in the Anti-Obesity Drugs Landscape

The anti-obesity drugs landscape is being reshaped by three converging forces: stronger clinical efficacy, broader medical recognition of obesity, and rising demand for long-term cardiometabolic risk management. Modern incretin-based therapies have reset patient and clinician expectations, with pivotal trials for semaglutide and tirzepatide showing double-digit average weight reduction under supervised treatment.

This transformation is also creating operational pressure. Demand has tested manufacturing capacity for injectable therapies, while payers are evaluating coverage through clinical value, durability of response, comorbidity reduction, safety profile, and total cost of care. Telehealth, employer-sponsored obesity programs, and integrated diabetes-obesity clinics are accelerating patient access, but they also raise expectations for appropriate prescribing, adherence monitoring, lifestyle support, and long-term safety surveillance.

Cumulative Impact of Artificial Intelligence on Anti-Obesity Drugs

Artificial intelligence is compounding value across the anti-obesity drugs lifecycle. In discovery, AI-enabled modeling supports target identification, peptide optimization, formulation screening, and prediction of off-target effects. In development, machine learning can improve trial feasibility by identifying eligible patients, modeling dropout risk, and supporting adaptive evidence-generation strategies.

The cumulative impact is greatest when AI connects clinical, real-world, and operational data. Predictive analytics can support dose optimization, adverse-event detection, adherence interventions, patient stratification, and supply forecasting for high-demand therapies. For industry leaders, the priority is not simply AI adoption, but validated, auditable AI governance that aligns with regulatory expectations, privacy laws, and clinical accountability in obesity care.

Key Regional Insights for Anti-Obesity Drugs

North America remains a leading anti-obesity drugs region due to high obesity prevalence, early adoption of GLP-1 based therapies, established specialist networks, and active FDA-regulated approvals. The CDC reported that adult obesity prevalence in the United States remained above 40% in recent national survey periods, reinforcing demand for evidence-based obesity pharmacotherapy. Europe is advancing through EMA-regulated access, national health technology assessments, and growing clinical recognition of obesity as a chronic disease, although reimbursement remains uneven across countries and often depends on comorbidity thresholds, treatment duration rules, and budget-impact reviews.

Asia-Pacific is positioned for rapid growth as China, India, Japan, South Korea, and Australia confront rising obesity, type 2 diabetes, and cardiovascular risk linked to urbanization, dietary change, and aging populations. Latin America, led by Brazil and Mexico, shows strong medical need as obesity and diabetes burdens increase, but affordability, insurance coverage, and fragmented care pathways continue to shape access. The Middle East, particularly Gulf markets, has high obesity and diabetes prevalence that supports demand for advanced anti-obesity medications, specialist endocrinology care, and government-led chronic disease programs. Africa presents long-term potential, shaped by urbanization, dual malnutrition burdens, uneven diagnostic capacity, and the need for affordable, scalable obesity-care pathways that can be integrated into primary care.

Key Group Insights for Anti-Obesity Drugs

Within ASEAN, anti-obesity drug development is shaped by diverse income levels, expanding private healthcare, and increasing obesity-related diabetes across urban populations, with access differing significantly between advanced health systems and lower-resource settings. The GCC is a high-priority cluster because obesity and diabetes are major public-health priorities, and government-backed healthcare modernization supports specialty prescribing, chronic disease screening, digital health deployment, and broader cardiometabolic care integration.

The European Union provides a harmonized regulatory pathway through the EMA, but pricing and reimbursement remain country specific, requiring evidence packages that address national health technology assessment expectations. BRICS countries combine large patient pools with wide access variation, making localization, affordability, local clinical evidence, and domestic partnerships important for anti-obesity medications. G7 markets anchor innovation, clinical evidence generation, regulatory precedent, and premium reimbursement discussions, especially where obesity is managed alongside diabetes and cardiovascular disease. NATO is not a healthcare trade bloc, but many NATO members overlap with advanced pharmaceutical markets where supply security, cold-chain resilience, pharmacovigilance systems, and regulatory alignment influence anti-obesity drug availability.

Key Country Insights for Anti-Obesity Drugs

The United States is the most influential commercial country for anti-obesity drugs, supported by high obesity prevalence, FDA approvals, employer demand, active specialist prescribing, and strong specialty distribution, while Canada is expanding evidence-based access through public and private payer review. Mexico and Brazil show rising need due to obesity and diabetes burdens, with access shaped by affordability, insurance design, physician availability, and health-system fragmentation.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are guided by national reimbursement and health technology assessment priorities that assess clinical benefit, treatment eligibility, safety, and budget impact, while Russia faces a more complex access and supply environment. China and India offer major long-term patient-volume potential because of large populations, rising metabolic disease prevalence, and expanding healthcare investment, but pricing, local evidence, regulatory pathways, and domestic competition matter. Japan, Australia, and South Korea combine advanced healthcare systems with strong regulatory standards, aging populations, and growing cardiometabolic-care demand, making physician education, reimbursement clarity, and long-term outcomes evidence central to adoption.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize durable clinical differentiation, real-world evidence, and payer-ready value propositions that connect weight loss with cardiometabolic outcomes, quality of life, medication persistence, and healthcare utilization. Companies should invest in manufacturing resilience, device capacity, cold-chain planning, quality assurance, and demand forecasting to reduce supply disruptions in high-demand markets.

Commercial strategies should pair specialist education with responsible patient access models, including obesity screening, contraindication review, nutrition support, physical activity guidance, behavioral care, and long-term adherence programs. AI initiatives should be deployed under clear governance, bias testing, data privacy safeguards, and pharmacovigilance controls. Partnerships with payers, employers, digital health platforms, public-health stakeholders, and local distributors can strengthen access while supporting equitable, medically appropriate obesity treatment.

Research Methodology for Anti-Obesity Drugs Analysis

This executive summary is built on a structured secondary-research methodology using verified public-health, regulatory, and clinical sources. Inputs include World Health Organization obesity statistics, national public-health agencies such as the CDC, regulatory information from the FDA and EMA, peer-reviewed clinical trial publications, clinical practice guidance, and health-system evidence from OECD and national reimbursement bodies.

The analysis triangulates epidemiology, approved therapies, clinical outcomes, access dynamics, reimbursement signals, regional healthcare infrastructure, and supply-chain considerations. Market interpretation emphasizes evidence-backed drivers and restraints, avoiding unsupported projections. Keyword mapping reflects industry terminology used by pharmaceutical executives, investors, healthcare strategists, and policy stakeholders evaluating anti-obesity drugs, GLP-1 therapies, obesity pharmacotherapy, incretin-based treatments, weight management medications, and cardiometabolic disease management.

Conclusion on the Anti-Obesity Drugs Market

The anti-obesity drugs market is entering a new phase defined by high clinical expectations, expanding treatment eligibility, and closer integration with cardiometabolic care. Incretin-based therapies have changed the standard for pharmacologic weight management, while cardiovascular outcomes evidence is strengthening the case for obesity treatment as preventive medicine.

Future leadership will depend on more than efficacy alone. Companies that combine differentiated science, reliable supply, evidence-based reimbursement strategies, responsible AI, and equitable access models will be best positioned. As obesity prevalence continues to rise worldwide, anti-obesity medications are set to remain a strategic priority for healthcare systems, pharmaceutical innovators, and investors focused on long-term chronic disease management.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Anti-Obesity Drugs Market, by Product Type
7.1. Glp-1 Agonists
7.2. Naltrexone Bupropion
7.3. Orlistat
7.4. Phentermine Topiramate
7.5. Sglt2 Inhibitors
8. Anti-Obesity Drugs Market, by Dosage Form
8.1. Capsules
8.2. Injectables
8.2.1. Prefilled Pens
8.2.2. Vials
8.3. Tablets
9. Anti-Obesity Drugs Market, by Route Of Administration
9.1. Injectable
9.1.1. Autoinjector
9.1.2. Prefilled Pen
9.1.3. Vial
9.2. Nasal
9.3. Oral
10. Anti-Obesity Drugs Market, by End User
10.1. Clinics
10.2. Homecare Settings
10.3. Hospitals
11. Asia-Pacific Anti-Obesity Drugs Market
12. Europe Anti-Obesity Drugs Market
13. North America Anti-Obesity Drugs Market
14. Latin America Anti-Obesity Drugs Market
15. Africa Anti-Obesity Drugs Market
16. Middle East Anti-Obesity Drugs Market
17. NATO Anti-Obesity Drugs Market
18. G7 Anti-Obesity Drugs Market
19. BRICS Anti-Obesity Drugs Market
20. European Union Anti-Obesity Drugs Market
21. ASEAN Anti-Obesity Drugs Market
22. GCC Anti-Obesity Drugs Market
23. China Anti-Obesity Drugs Market
24. United States Anti-Obesity Drugs Market
25. Japan Anti-Obesity Drugs Market
26. India Anti-Obesity Drugs Market
27. Germany Anti-Obesity Drugs Market
28. United Kingdom Anti-Obesity Drugs Market
29. Australia Anti-Obesity Drugs Market
30. France Anti-Obesity Drugs Market
31. South Korea Anti-Obesity Drugs Market
32. Italy Anti-Obesity Drugs Market
33. Canada Anti-Obesity Drugs Market
34. Russia Anti-Obesity Drugs Market
35. Brazil Anti-Obesity Drugs Market
36. Mexico Anti-Obesity Drugs Market
37. Spain Anti-Obesity Drugs Market
38. Competitive Landscape
38.1. Market Concentration Analysis, 2025
38.1.1. Concentration Ratio (CR)
38.1.2. Herfindahl Hirschman Index (HHI)
38.2. Recent Developments & Impact Analysis, 2025
38.3. Product Portfolio Analysis, 2025
38.4. Benchmarking Analysis, 2025
39. Company Profiles
39.1. Alvogen Iceland EHF
39.2. Amgen Inc
39.3. AstraZeneca plc
39.4. Bayer AG
39.5. Boehringer Ingelheim International GmbH
39.6. Cipla Ltd.
39.7. Currax Pharmaceuticals LLC
39.8. Dr. Reddy’s Laboratories Ltd.
39.9. Eli Lilly and Company
39.10. F Hoffmann La Roche Ltd
39.11. Gelesis Holdings Inc.
39.12. GlaxoSmithKline plc
39.13. Hanmi Pharmaceutical Co., Ltd.
39.14. Innovent Biologics Inc
39.15. Intas Pharmaceuticals Ltd.
39.16. LG Chem Ltd
39.17. Merck and Co Inc
39.18. Novartis AG
39.19. Novo Nordisk A S
39.20. Pfizer Inc
39.21. Rhythm Pharmaceuticals Inc
39.22. Sanofi S.A.
39.23. Sun Pharmaceutical Industries Ltd.
39.24. Takeda Pharmaceutical Company Limited
39.25. Teva Pharmaceutical Industries Ltd
39.26. Zealand Pharma A/S
39.27. Zydus Lifesciences Ltd
List of Figures
FIGURE 1. GLOBAL ANTI-OBESITY DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ANTI-OBESITY DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ANTI-OBESITY DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ANTI-OBESITY DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ANTI-OBESITY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL ANTI-OBESITY DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 23. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 25. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 35. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 37. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. CHINA ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 47. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 48. JAPAN ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 49. INDIA ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 50. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. AUSTRALIA ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. SOUTH KOREA ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. ITALY ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. CANADA ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ANTI-OBESITY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ANTI-OBESITY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL ANTI-OBESITY DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL GLP-1 AGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL GLP-1 AGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL GLP-1 AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL NALTREXONE BUPROPION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL NALTREXONE BUPROPION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL NALTREXONE BUPROPION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ORLISTAT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ORLISTAT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ORLISTAT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL PHENTERMINE TOPIRAMATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL PHENTERMINE TOPIRAMATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL PHENTERMINE TOPIRAMATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL SGLT2 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL SGLT2 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL SGLT2 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL INJECTABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL INJECTABLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL PREFILLED PENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL PREFILLED PENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL PREFILLED PENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL VIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL VIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL VIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL AUTOINJECTOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL AUTOINJECTOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL AUTOINJECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL PREFILLED PEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL PREFILLED PEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL PREFILLED PEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL VIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL VIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL VIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL NASAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL NASAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL NASAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 71. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 72. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 73. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 74. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 75. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 76. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 78. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 79. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 80. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 81. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 82. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 83. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 85. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 86. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 87. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 88. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 89. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 90. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 92. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 93. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 94. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 95. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 96. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 97. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 99. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 100. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 101. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 102. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 103. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 104. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 105. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 106. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 107. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 108. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 109. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 110. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 111. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 112. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 113. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 114. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 115. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 116. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 117. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 118. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 119. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 120. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 121. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 122. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 123. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 124. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 125. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 126. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 127. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 128. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 129. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 130. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 131. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 132. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 133. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 134. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 135. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 136. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 137. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 138. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 139. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 140. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 141. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 142. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 143. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 144. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 145. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 146. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 147. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 148. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 149. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 150. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 151. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 152. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 153. CHINA ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 154. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 155. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 156. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 157. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 158. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 159. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 160. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 161. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 162. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 163. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 164. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 165. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 166. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 167. JAPAN ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 168. JAPAN ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 169. JAPAN ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 170. JAPAN ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 171. JAPAN ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 172. JAPAN ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 173. JAPAN ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 174. INDIA ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 175. INDIA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 176. INDIA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 177. INDIA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 178. INDIA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 179. INDIA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 180. INDIA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 181. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 182. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 183. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 184. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 185. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 186. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 187. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 188. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 189. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 190. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 191. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 192. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 193. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 194. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 195. AUSTRALIA ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 196. AUSTRALIA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 197. AUSTRALIA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 198. AUSTRALIA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 199. AUSTRALIA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 200. AUSTRALIA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 201. AUSTRALIA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 202. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 203. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 204. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 205. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 206. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 207. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 208. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 209. SOUTH KOREA ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 210. SOUTH KOREA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 211. SOUTH KOREA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 212. SOUTH KOREA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 213. SOUTH KOREA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 214. SOUTH KOREA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 215. SOUTH KOREA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 216. ITALY ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 217. ITALY ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 218. ITALY ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 219. ITALY ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 220. ITALY ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 221. ITALY ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 222. ITALY ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 223. CANADA ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 224. CANADA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 225. CANADA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 226. CANADA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 227. CANADA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 228. CANADA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 229. CANADA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 230. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 231. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 232. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 233. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 234. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 235. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 236. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 237. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 238. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 239. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 240. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 241. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 242. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 243. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 244. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 245. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 246. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 247. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 248. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 249. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 250. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 251. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 252. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 253. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 254. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 255. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 256. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 257. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The companies featured in this Anti-Obesity Drugs market report include:
  • Alvogen Iceland EHF
  • Amgen Inc
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Cipla Ltd.
  • Currax Pharmaceuticals LLC
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • F Hoffmann La Roche Ltd
  • Gelesis Holdings Inc.
  • GlaxoSmithKline plc
  • Hanmi Pharmaceutical Co., Ltd.
  • Innovent Biologics Inc
  • Intas Pharmaceuticals Ltd.
  • LG Chem Ltd
  • Merck and Co Inc
  • Novartis AG
  • Novo Nordisk A S
  • Pfizer Inc
  • Rhythm Pharmaceuticals Inc
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
  • Zealand Pharma A/S
  • Zydus Lifesciences Ltd

Table Information

Report AttributeDetails
No. of Pages198
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 11.21 Billion
Forecasted Market Value ( USD ) by 2032 $ 22.59 Billion
Compound Annual Growth Rate12.3%
Regions CoveredGlobal
No. of Companies Mentioned28

Related Topics

Related Reports

Anti-Obesity Drugs Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Molecule, Active Compound Used, Mechanism of Action, Type of Agonist, Action Pathway, Route of Administration, Geographical Regions, Sales Forecast and Key Players - Product Image

Anti-Obesity Drugs Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Molecule, Active Compound Used, Mechanism of Action, Type of Agonist, Action Pathway, Route of Administration, Geographical Regions, Sales Forecast and Key Players

  • Report
  • 240 Pages
  • Global
From
North America Anti-Obesity Drugs Market Size, Share & Industry Trends Analysis Report By Drug Type, By Mechanism of Action, By Route Of Administration (Oral Route and Subcutaneous Route), By Distribution Channel, By Country and Growth Forecast, 2023-2029 - Product Image

North America Anti-Obesity Drugs Market Size, Share & Industry Trends Analysis Report By Drug Type, By Mechanism of Action, By Route Of Administration (Oral Route and Subcutaneous Route), By Distribution Channel, By Country and Growth Forecast, 2023-2029

  • Report
  • 72 Pages
  • North America
From
Asia Pacific Anti-Obesity Drugs Market Report and Forecast 2024-2032 - Product Image

Asia Pacific Anti-Obesity Drugs Market Report and Forecast 2024-2032

  • Report
  • 140 Pages
  • Asia Pacific
From
Anti-Obesity Drugs - Global Strategic Business Report - Product Image

Anti-Obesity Drugs - Global Strategic Business Report

  • Report
  • 121 Pages
  • Global
From
Anti-obesity Prescription Drugs Market by Drug Class, Dosage Form, Therapy Type, Application, End User, Distribution Channel - Global Forecast 2026-2032 - Product Image

Anti-obesity Prescription Drugs Market by Drug Class, Dosage Form, Therapy Type, Application, End User, Distribution Channel - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.